Pfizer News | finanzen.ch

Pfizer Aktie VALOR 1065272 / ISIN ARDEUT111424

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Trading-Depot	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Trading-Depot

Aktion

Portfolio

Watchlist

11.07.24	Pfizer Advances Development of Once-Daily Formulation of Oral GLP-1 Receptor Agonist Danuglipron (Businesswire)
09.07.24	Pfizer to Launch Process to Identify a Successor for Dr. Mikael Dolsten, Chief Scientific Officer and President, Pfizer Research & Development (Businesswire)
01.07.24	Cyrus Taraporevala Elected to Pfizer’s Board of Directors (Businesswire)
27.06.24	Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union (RSS)
27.06.24	Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union (Businesswire)
26.06.24	Pfizer Declares Third-Quarter 2024 Dividend (Businesswire)
18.06.24	Pfizer Invites Public to View and Listen to Webcast of July 30 Conference Call with Analysts (Businesswire)
14.06.24	ELREXFIO™ Shows Median Overall Survival of More Than Two Years in People with Relapsed or Refractory Multiple Myeloma (Businesswire)
12.06.24	Pfizer Provides Update on Phase 3 Study of Investigational Gene Therapy for Ambulatory Boys with Duchenne Muscular Dystrophy (Businesswire)
03.06.24	Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference (Businesswire)
01.06.24	Pfizer’s ADCETRIS® Regimen Produces Clinically Meaningful Improvement in Overall Survival in Patients with Relapsed/?Refractory Diffuse Large B-cell Lymphoma (DLBCL) (Businesswire)
31.05.24	Pfizer’s LORBRENA® CROWN Study Shows Majority of Patients with ALK-Positive Advanced Lung Cancer Living Beyond Five Years Without Disease Progression (Businesswire)
14.05.24	NVIDIA, Amazon, Apple & Co.: Das sind die am meisten bewunderten Unternehmen der Welt (finanzen.ch) Jedes Jahr erstellt Fortune ein Ranking mit den "World’s Most Admired Companies". In diesem Jahr kamen die Top Ten Unternehmen alle aus den USA.» mehr
06.05.24	Pfizer Announces New Chief Strategy and Innovation Officer (Businesswire)
01.05.24	Pfizer Reports First-Quarter 2024 Results (Businesswire)
30.04.24	FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer (Businesswire)
29.04.24	Pfizer Highlights Progress in Accelerating Breakthrough Cancer Medicines at ASCO 2024 Annual Meeting (Businesswire)
26.04.24	U.S. FDA Approves Pfizer’s BEQVEZ™ (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia B (Businesswire)
24.04.24	Pfizer Declares Second-Quarter 2024 Dividend (Businesswire)
22.04.24	European Commission Approves Pfizer’s EMBLAVEO® for Patients with Multidrug-Resistant Infections and Limited Treatment Options (Businesswire)
11.04.24	Pfizer Invites Shareholders to Attend Virtual-Only 2024 Annual Meeting of Shareholders on April 25 (Businesswire)
09.04.24	Pfizer Announces Positive Top-Line Results from Phase 3 Study of ABRYSVO® in Adults Aged 18 to 59 at Increased Risk for RSV Disease (Businesswire)
20.03.24	Pfizer Invites Public to View and Listen to Webcast of May 1 Conference Call with Analysts (Businesswire)
13.03.24	European Commission Approves Pfizer’s PREVENAR 20® to Help Protect Infants and Children Against Pneumococcal Disease (Businesswire)
12.03.24	Pfizer Announces Positive Overall Survival in Phase 3 Trial of ADCETRIS® Regimen in Patients with Relapsed/?Refractory Diffuse Large B-cell Lymphoma (DLBCL) (Businesswire)
05.03.24	Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference (Businesswire)
29.02.24	Pfizer Oncology Hosts Innovation Day, Highlighting Fully Integrated Organization, Robust Portfolio, and Strategic Priorities to Drive Long-Term Sustainable Growth (Businesswire)
29.02.24	Pfizer Announces Positive Top-Line Data for Full Season Two Efficacy of ABRYSVO® for RSV in Older Adults (Businesswire)
26.02.24	Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference (Businesswire)
19.02.24	European Commission Approves Pfizer’s VELSIPITY® for Patients with Moderately to Severely Active Ulcerative Colitis (Businesswire)
15.02.24	Pfizer Invites Public to Register for Webcast of Pfizer Oncology Innovation Day (Businesswire)
05.02.24	Breaking Barriers in Cancer Care: The American Cancer Society and Pfizer Announce a $15 Million, Three-Year Initiative to Bridge the Gap in Cancer Care Disparities (Businesswire)
30.01.24	Pfizer Reports Full-Year 2023 Results and Reaffirms Full-Year 2024 Financial Guidance (Businesswire)
26.01.24	European Medicines Agency Validates Type II Variation Application for PADCEV® (enfortumab vedotin) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer (Businesswire)
10.01.24	Pfizer Recommends Shareholders Reject the Below-Market Mini-Tender Offer by TRC Capital Investment Corporation (Businesswire)
09.01.24	TIVDAK® Supplemental Biologics License Application Accepted for Priority Review by FDA for Patients with Recurrent or Metastatic Cervical Cancer (Businesswire)
08.01.24	European Commission Approves Pfizer’s TALZENNA® in Combination with XTANDI® for Adult Patients with Metastatic Castration-Resistant Prostate Cancer (Businesswire)
02.01.24	Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference (Businesswire)
19.12.23	Pfizer Invites Public to View and Listen to Webcast of January 30 Conference Call with Analysts (Businesswire)
15.12.23	PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder Cancer (Businesswire)
14.12.23	Pfizer Declares First-Quarter 2024 Dividend (Businesswire)
14.12.23	Pfizer Completes Acquisition of Seagen (Businesswire)
13.12.23	Pfizer Provides Full-Year 2024 Guidance (Businesswire)
12.12.23	Pfizer Receives All Required Regulatory Approvals to Complete the Acquisition of Seagen (Businesswire)
10.12.23	Marstacimab Phase 3 Data Presented at ASH 2023 Demonstrate Significant Bleed Reduction in Hemophilia A and B (Businesswire)
08.12.23	European Commission Approves Pfizer’s ELREXFIO® for Relapsed and Refractory Multiple Myeloma (Businesswire)
01.12.23	Pfizer Announces Topline Phase 2b Results of Oral GLP-1R Agonist, Danuglipron, in Adults with Obesity (Businesswire)
21.11.23	Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference (Businesswire)
17.11.23	Aktienempfehlungen konträr: Diese Low-Performer könnten die Top-Aktien 2024 werden (finanzen.ch) Mark Hulbert verrät, welche Low-Performer aus dem laufenden Jahr zu Top-Titeln 2024 werden könnten.» mehr
02.11.23	Pfizer Highlights Scientific Advances from Growing Hematology Portfolio at American Society of Hematology Annual Meeting (Businesswire)

Erfolgreich hinzugefügt!. Zu Portfolio/Watchlist wechseln.

Es ist ein Fehler aufgetreten!

Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben. Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	97.46	2.65 %	K V
Part Grp Hldg	967.00	2.59 %	K V
ABB	57.06	1.67 %	K V
Holcim	71.46	1.59 %	K V
Roche Hldg G	272.40	1.49 %	K V
Nestle	79.10	-0.03 %	K V
Novartis	101.94	-0.06 %	K V
Zurich Insur Gr	564.80	-0.32 %	K V
Swiss Life Hldg	870.60	-0.32 %	K V
Swisscom	595.50	-1.24 %	K V